MA1-7657

antibody from Invitrogen Antibodies

Targeting: TFRC CD71, p90, TFR1

Flow cytometry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA1-7657

Provider

Invitrogen Antibodies

Product name

Transferrin Receptor Monoclonal Antibody (ICO-92)

Antibody type

Monoclonal

Antigen

Other

Description

MA1-7657 detects Transferrin receptor from human samples. MA1-7657 has been successfully used in flow cytometry procedures. The MA1-7657 immunogen is a Transferrin receptor on activated T-B-cells.

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

ICO-92

Vial size

100 µg

Concentration

1 mg/mL

Storage

4°C short term, -80°C long term

References

Submitted references

Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers.

Sitia L, Sevieri M, Bonizzi A, Allevi R, Morasso C, Foschi D, Corsi F, Mazzucchelli S
ACS omega 2020 Jun 2;5(21):12035-12045

---

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines.

Bonizzi A, Truffi M, Sevieri M, Allevi R, Sitia L, Ottria R, Sorrentino L, Sottani C, Negri S, Grignani E, Mazzucchelli S, Corsi F
Pharmaceutics 2019 Aug 2;11(8)

---

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.

Mazzucchelli S, Truffi M, Baccarini F, Beretta M, Sorrentino L, Bellini M, Rizzuto MA, Ottria R, Ravelli A, Ciuffreda P, Prosperi D, Corsi F
Scientific reports 2017 Aug 8;7(1):7505

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 1 HFn specific interaction with CC lines. TfR1 expressionof CC linestested by cytofluorimetry expressed as mean fluorescence intensity(a) and as percentage of positive cells (b). Cells immunodecoratedwith the anti-mouse secondary antibody conjugated with Alexa Fluor488 were used to set the gate on viable cells, on singlets, and theregion of positivity. (c) HFn-F binding with CCs. Cells wereincubated 2 h at 4 degC in PBS buffer and 0.3% BSA with differentamounts of HFn-F (20 and 100 mug/mL). Cells were processedfor flow cytometry using untreated cells to set the positive regionand the singlet gate. (d) Competition assay in HT-29 cells (high TfR1expression) incubated with 500 muL of HFn-F (20 mug/mL)at 4 degC for 2 h with or without an excess of unlabeled HFn (1 mg/mL) as competitor. Cells were then detached and treated for flowcytometry. Untreated cells have been used to set the singlet gateand the positive region. Data are reported as average +- S.D.of three independent experiments and expressed as panel (a), meanfluorescence intensity (M.F.I., x10 5 ); panel (b),percentage of cells in the positive region to HFn-F fluorescenceand; panel (c), relative fluorescence intensity (R.F.I., %).

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 HFn-ICGinteraction with TfR1 low CCs. (a-c)Representative flow cytometry plots showing cell binding with 20,50, and 100 mug/mL of HFn-ICG (light green, purple, andblue curves, respectively, black curves = control cells) after 2 hincubation at 4 degC. (d-f) Representative confocal microscopyimages of cells incubated with HFn-ICG for 2 h at 4 degCto evaluate binding and TfR1 colocalization (blue = cell nuclei stainedwith DAPI, cyan = cell membranes, green = HFn-ICG, and purple= alphaTfR1 antibody staining). (g-i) Cellular uptake ofHFn-ICG evaluated by IVIS analysis, after incubation at 37degC for different time points. Low TfR1 expressions lead to lowbinding, low uptake, and low colocalization with TfR1.